과제정보
We wish to thank all the individuals who are living with rare diseases, their families, and the clinical and research laboratory staff.
참고문헌
- Melbouci M, Mason RW, Suzuki Y, Fukao T, Orii T, Tomatsu S. Growth impairment in mucopolysaccharidoses. Mol Genet Metab 2018;124:1-10. https://doi.org/10.1016/j.ymgme.2018.03.004
- Rozdzynska-Swiatkowska A, Jurecka A, Cieslik J, Tylki-Szymanska A. Growth patterns in children with mucopolysaccharidosis I and II. World J Pediatr 2015;11:226-31. https://doi.org/10.1007/s12519-014-0517-6
- Rogers DG, Nasomyont N. Growth hormone treatment in a patient with Hurler-Scheie syndrome. J Pediatr Endocrinol Metab 2014;27:957-60. https://doi.org/10.1515/jpem-2013-0340
- Polgreen LE, Thomas W, Orchard PJ, Whitley CB, Miller BS. Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome. Mol Genet Metab 2014;111:101-6. https://doi.org/10.1016/j.ymgme.2013.11.013
- Hardin DS. Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin). Biologics 2008;2:655-61.
- Patel P, Suzuki Y, Maeda M, Yasuda E, Shimada T, Orii KE, et al. Growth charts for patients with Hunter syndrome. Mol Genet Metab Rep 2014;1:5-18. https://doi.org/10.1016/j.ymgmr.2013.10.001
- Polgreen LE, Miller BS. Growth patterns and the use of growth hormone in the mucopolysaccharidoses. J Pediatr Rehabil Med 2010;3:25-38. https://doi.org/10.3233/PRM-2010-0106
- Cattoni A, Motta S, Masera N, Gasperini S, Rovelli A, Parini R. The use of recombinant human growth hormone in patients with Mucopolysaccharidoses and growth hormone deficiency: a case series. Ital J Pediatr 2019;45:93.
- Jiang Z, Byers S, Casal ML, Smith LJ. Failures of endochondral ossification in the mucopolysaccharidoses. Curr Osteoporos Rep 2020;18:759-73. https://doi.org/10.1007/s11914-020-00626-y
- Collett-Solberg PF, Jorge AAL, Boguszewski MCS, Miller BS, Choong CSY, Cohen P, et al. Growth hormone therapy in children; research and practice - a review. Growth Horm IGF Res 2019;44:20-32. https://doi.org/10.1016/j.ghir.2018.12.004
- Chen HH, Sawamoto K, Mason RW, Kobayashi H, Yamaguchi S, Suzuki Y, et al. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future. J Hum Genet 2019;64:1153-71. https://doi.org/10.1038/s10038-019-0662-9
- Tanaka N, Katsumata N, Horikawa R, Tanaka T. The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia. Endocr J 2003;50:69-75. https://doi.org/10.1507/endocrj.50.69
- Miccoli M, Bertelloni S, Massart F. Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis. Horm Res Paediatr 2016;86:27-34. https://doi.org/10.1159/000446958
- Ramaswami U, Rumsby G, Spoudeas HA, Hindmarsh PC, Brook CG. Treatment of achondroplasia with growth hormone: six years of experience. Pediatr Res 1999;46:435-9. https://doi.org/10.1203/00006450-199910000-00012
- Polgreen LE, Plog M, Schwender JD, Tolar J, Thomas W, Orchard PJ, et al. Short-term growth hormone treatment in children with Hurler syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2009;44:279-85. https://doi.org/10.1038/bmt.2009.31
- Kandemir N, Gonc EN, Yordam N. Responses of bone turnover markers and bone mineral density to growth hormone therapy in children with isolated growth hormone deficiency and multiple pituitary hormone deficiencies. J Pediatr Endocrinol Metab 2002;15:809-16. https://doi.org/10.1515/JPEM.2002.15.6.809
- Ali O, Shim M, Fowler E, Greenberg M, Perkins D, Oppenheim W, et al. Growth hormone therapy improves bone mineral density in children with cerebral palsy: a preliminary pilot study. J Clin Endocrinol Metab 2007;92:932-7. https://doi.org/10.1210/jc.2006-0385